LYTGOBI 4mg film-coated tablets medication leaflet

L01EN04 • futibatinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

Futibatinib is a medication used to treat certain cancers, particularly cholangiocarcinoma (bile duct cancer), in patients with an FGFR2 gene mutation. It works by blocking FGFR receptors, which are involved in the uncontrolled growth of cancer cells.

The drug is taken orally as tablets, and the dose is determined by the doctor based on the patient's condition and the stage of the disease. Treatment is ongoing and requires regular medical assessments to monitor its effectiveness and safety.

Common side effects include nausea, dry mouth, diarrhea, fatigue, and changes in blood phosphate levels. In some cases, eye or liver problems may occur, so regular check-ups, including ophthalmological evaluations, are recommended.

Futibatinib provides a valuable option for patients with rare and hard-to-treat cancers, but its use must be closely monitored by healthcare professionals to prevent and manage possible complications.